<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01379807</url>
  </required_header>
  <id_info>
    <org_study_id>GGIO-2010-01</org_study_id>
    <nct_id>NCT01379807</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Panitumumab Combined With Docetaxel and Cisplatin as a First-line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma</brief_title>
  <acronym>SPIGA</acronym>
  <official_title>A Phase II Trial to Assess the Efficacy and Safety of Panitumumab Combined With Docetaxel and Cisplatin as a First-line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo Gallego de Investigaciones Oncologicas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Trial Form Support S.L.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Grupo Gallego de Investigaciones Oncologicas</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The clinical hypothesis of this study is that the addition of Panitumumab to the first line&#xD;
      treatment combination of docetaxel plus cisplatin will provide benefit to patients with&#xD;
      advanced gastric or gastroesophageal junction adenocarcinoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>December 2010</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>3 years</time_frame>
    <description>To estimate the objective response rate in patients treated with docetaxel, cisplatin and panitumumab as first-line treatment in advanced gastric or gastroesophageal junction adenocarcinoma.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to treatment failure</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of stable disease</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety profile</measure>
    <time_frame>3 years</time_frame>
    <description>To describe the safety profile of this combination therapy in the 1st-line setting including the incidence of AE's and changes in laboratory parameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exploratory Objectives</measure>
    <time_frame>3 years</time_frame>
    <description>To investigate the predictive potential of different biomarkers on efficacy and/or safety endpoints.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Gastric Adenocarcinoma</condition>
  <condition>Gastroesophageal Junction Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>panitumumab + docetaxel + cisplatino</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>panitumumab + docetaxel + cisplatino</intervention_name>
    <description>Panitumumab, docetaxel and cisplatin combination treatment will be administered for 6 months or until disease progression (PD) according to investigator's criteria unacceptable toxicity or consent withdrawal.</description>
    <arm_group_label>panitumumab + docetaxel + cisplatino</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent Inclusion:&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Histologically or cytologically confirmed adenocarcinoma of the stomach or&#xD;
             gastroesophageal junction with advanced unresectable or metastatic disease.&#xD;
&#xD;
          -  Measurable disease per the revised RECIST (Response Evaluation Criteria in Solid&#xD;
             Tumor) Guidelines&#xD;
&#xD;
          -  ECOG performance score of 0 - 2&#xD;
&#xD;
          -  Within seven days prior to initiating study treatment:Haematology:Neutrophils ≥&#xD;
             1.5x109, Platelets ≥ 100x10/ L, Hemoglobin ≥ 9g/dL. Hepatic functions: Total bilirubin&#xD;
             ≤ 1.5 time the upper normal limit (UNL),ASAT ≤ 2.5xUNL in absence of liver metastases,&#xD;
             or ≤5xUNL in presence of liver metastases,ALAT ≤ 2.5xUNL in absence of liver&#xD;
             metastases, or ≤5xUNL in presence of liver metastases. Renal function: creatinine&#xD;
             clearance ≥50 mL/min. Metabolic Function: Magnesium ≥ lower limit of normal, Calcium ≥&#xD;
             lower limit of normal.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior chemotherapy or other anticancer therapy for advanced unresectable or metastatic&#xD;
             disease (1st line)&#xD;
&#xD;
          -  Prior anti-EGFR antibody therapy (e.g. cetuximab) or treatment with small molecule&#xD;
             EGFR inhibitors (e.g. erlotinib).&#xD;
&#xD;
          -  HER2-positive tumor (centrally assessed)&#xD;
&#xD;
          -  Past or current history (within the last 5 years prior to treatment start) of other&#xD;
             malignancies except gastric cancer (Patients with curatively treated basal and&#xD;
             squamous cell carcinoma of the skin or in situ carcinoma of the cervix are eligible)&#xD;
&#xD;
          -  Current or prior history of central nervous system metastases&#xD;
&#xD;
          -  Evidence of any other disease, metabolic dysfunction, physical examination finding or&#xD;
             laboratory finding giving reasonable suspicion of a disease or condition that&#xD;
             contraindicates the use of an investigational drug or puts the patient at high risk&#xD;
             for treatment-related complications Treatment with any other investigational agent, or&#xD;
             participation in another clinical trial within 30 days prior to entering this study&#xD;
&#xD;
          -  Known hypersensitivity to any of the study drugs&#xD;
&#xD;
          -  Clinically significant cardiovascular disease (including myocardial infarction,&#xD;
             unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac&#xD;
             arrhythmia) ≤ 1 year before enrollment&#xD;
&#xD;
          -  History of interstitial lung disease e.g. pneumonitis or pulmonary fibrosis or&#xD;
             evidence of interstitial lung disease on baseline chest CT scan.&#xD;
&#xD;
          -  Subject pregnant or breast feeding, or planning to become pregnant within 6 months&#xD;
             after the end of treatment.&#xD;
&#xD;
          -  Subject (male or female) is not willing to use highly effective methods of&#xD;
             contraception (per institutional standard) during treatment and for 6 months (male or&#xD;
             female) after the end of treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital Arquitecto Mercide</name>
      <address>
        <city>Ferrol</city>
        <state>La Coruña</state>
        <zip>15405</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Santiago (CHUS)</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>La Coruña</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Vigo (Xeral Cies)</name>
      <address>
        <city>Vigo</city>
        <state>Pontevedra</state>
        <zip>36204</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlínica de Vigo S.A.</name>
      <address>
        <city>Vigo</city>
        <state>Pontevedra</state>
        <zip>36211</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de A Coruña</name>
      <address>
        <city>La Coruña</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Oncológico de Galícia</name>
      <address>
        <city>La Coruña</city>
        <zip>15009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Lucus Augusti</name>
      <address>
        <city>Lugo</city>
        <zip>27003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Ourense</name>
      <address>
        <city>Ourense</city>
        <zip>32005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Pontevedra</name>
      <address>
        <city>Pontevedra</city>
        <zip>36002</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2011</verification_date>
  <study_first_submitted>June 22, 2011</study_first_submitted>
  <study_first_submitted_qc>June 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2011</study_first_posted>
  <last_update_submitted>March 10, 2015</last_update_submitted>
  <last_update_submitted_qc>March 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 11, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Panitumumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

